MedTrace Logo

Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221

NCT02146066 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2016-02-26

No results posted yet for this study

Summary

The study is an open-label expanded access study for patients for whom vaccine was manufactured during the Northwest Biotherapeutics' 020221 DCVax-L for GBM screening process, but who subsequently failed to meet specific enrollment criteria. Patients will receive therapy per investigator discretion (standard of care) as well as active vaccine per the 020221 protocol administration schedule. It is estimated that approximately 99 patients will enroll in this study.

Conditions

Interventions

BIOLOGICAL

DCVax-L

Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen

Sponsors & Collaborators

  • Northwest Biotherapeutics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02146066 on ClinicalTrials.gov